These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18516022)

  • 1. Is reduced-intensity conditioning the standard of care in the transplant setting?
    Giralt SA
    Clin Adv Hematol Oncol; 2008 May; 6(5):337-9. PubMed ID: 18516022
    [No Abstract]   [Full Text] [Related]  

  • 2. Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?
    Ringdén O; Sadeghi B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1615-7. PubMed ID: 23022465
    [No Abstract]   [Full Text] [Related]  

  • 3. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.
    Fielding AK; Goldstone AH
    Bone Marrow Transplant; 2008 Mar; 41(5):447-53. PubMed ID: 17968326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
    Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
    Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases.
    Ringdén O; Svenberg P; Le Blanc K; Mattsson J; Remberger M
    Bone Marrow Transplant; 2006 Aug; 38(4):321-2. PubMed ID: 16819434
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.
    Burt RK; Marmont A; Oyama Y; Slavin S; Arnold R; Hiepe F; Fassas A; Snowden J; Schuening F; Myint H; Patel DD; Collier D; Heslop H; Krance R; Statkute L; Verda L; Traynor A; Kozak T; Hintzen RQ; Rose JW; Voltarelli J; Loh Y; Territo M; Cohen BA; Craig RM; Varga J; Barr WG
    Arthritis Rheum; 2006 Dec; 54(12):3750-60. PubMed ID: 17133541
    [No Abstract]   [Full Text] [Related]  

  • 10. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?
    Hamadani M
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):292-4. PubMed ID: 24394802
    [No Abstract]   [Full Text] [Related]  

  • 11. Current European practice in pediatric myeloablative conditioning.
    Vettenranta K;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S14-7. PubMed ID: 18545236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current clinical problems in non-myeloablative reduced-intensity hematopoietic stem cell transplantation].
    Kanda Y
    Rinsho Ketsueki; 2002 Feb; 43(2):85-8. PubMed ID: 11925881
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced-intensity and nonmyeloablative conditioning regimens.
    Foss F; van Besien K
    Cancer Treat Res; 2009; 144():209-32. PubMed ID: 19779868
    [No Abstract]   [Full Text] [Related]  

  • 14. Antithymocyte globulin in the conditioning regimen: why not?
    Bacigalupo A
    Biol Blood Marrow Transplant; 2014 May; 20(5):597-8. PubMed ID: 24641827
    [No Abstract]   [Full Text] [Related]  

  • 15. [Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioned regimens].
    Popović SL
    Med Pregl; 2005; 58(9-10):435-6. PubMed ID: 16526242
    [No Abstract]   [Full Text] [Related]  

  • 16. Hematopoietic stem-cell transplantation for acute leukemia.
    Machida U; Kami M; Hirai H
    N Engl J Med; 1999 Mar; 340(10):810; author reply 811-2. PubMed ID: 10075530
    [No Abstract]   [Full Text] [Related]  

  • 17. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.
    van Besien K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2035-2036. PubMed ID: 26463649
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced-intensity conditioning in children: a reappraisal in 2008.
    Yaniv I; Stein J;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S18-22. PubMed ID: 18545237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?
    Turner BE; Collin M; Rice AM
    Cytotherapy; 2010 Jul; 12(4):440-54. PubMed ID: 20345215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.